Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins

Bayer, Andreas; Kuznik, Nadine; Langan, Ewan A.; Recke, Andreas; Recke, A. L.; Faerber, Gabriele; Kaschwich, Mark; Kleemann, Markus; Kahle, Birgit

doi:10.1016/j.jvsv.2020.05.015

Cited by 8 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With 0.5% polidocanol, the rate of hyperpigmentation was lower with liquid sclerosant (12.5%–30%) 7,10,13,14,17,18 than with foam (13%–67.9%) 10,13,15–17 . With polidocanol 1%, the rate of post‐treatment hyperpigmentation associated with liquid polidocanol 7,10,12–14,17,19,20 was higher than that associated with foam 10,13,16 (14.3%–73% vs. 14.8%–23%). The volumes used were not always mentioned in the publications.…”

Section: Resultsmentioning

confidence: 86%

“…The volumes used were not always mentioned in the publications. The maximum volumes for liquid polidocanol at all concentrations and foam polidocanol were 28 ml and 10 ml, respectively 7,9–20 …”

Section: Resultsmentioning

confidence: 97%

“…Liquid and foam with concentrations of 0.25%–1% were used to treat telangiectasias and reticular veins. The evaluation of all RCTs and non‐RCTs showed more hyperpigmentation with increasing concentrations: with polidocanol 0.25% (liquid and foam), the range of hyperpigmentation was 2%–25% 7,9–13 ; with polidocanol 0.5% (liquid and foam), the range of hyperpigmentation was 12.5%–67.9% 7,10,13–18 ; and with polidocanol 1% (liquid and foam), the range of hyperpigmentation was 13%–73% 7,10,12–14,16,17,19,20 …”

Section: Resultsmentioning

confidence: 99%

“…The evaluation of all RCTs and non-RCTs showed more hyperpigmentation with increasing concentrations: with polidocanol 0.25% (liquid and foam), the range of hyperpigmentation was 2%-25% 7,[9][10][11][12][13] ; with polidocanol 0.5% (liquid and foam), the range of hyperpigmentation was 12.5%-67.9% 7,10,[13][14][15][16][17][18] ; and with polidocanol 1% (liquid and foam), the range of hyperpigmentation was 13%-73%. 7,10,[12][13][14]16,17,19,20 A comparison of 0.25% polidocanol liquid and 0.25% polidocanol foam showed that the range of hyperpigmentation was comparable: 4.4%-25% for liquid polidocanol and 2%-20% for foam polidocanol. 7,[9][10][11][12][13] Two studies directly compared the side effects of 0.25% polidocanol liquid and 0.25% polidocanol foam.…”

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

“…The maximum volumes for liquid polidocanol at all concentrations and foam polidocanol were 28 ml and 10 ml, respectively. 7,[9][10][11][12][13][14][15][16][17][18][19][20] In all studies that included foam sclerotherapy with concentrations of 0.25%-1% polidocanol (seven studies), the foam was produced using the Tessari method. Two studies involving 0.25% polidocanol used the Monfreux technique.…”

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

See 4 more Smart Citations

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Skin hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol‐containing sclerosants was performed. Reported incidence rates, follow‐up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam) and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam) and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1%–3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol‐related sclerotherapy are poor and should be improved by higher‐quality research.

show abstract